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The recent emergence and rapid spread of the pandemic H1N1 swine influenza virus reminded us
once again of the need for a universal influenza vaccine that can elicit heterosubtypic protection.
Here, we show the superior immunogenicity and immunoprotective capacity of the full-length
matrix protein 2 ectodomain (M2e) peptide coupled to keyhole limpet haemocyanin (KLH)
compared with the N-terminal 9 aa residues of M2e (SP1). Immunization with M2e–KLH
protected mice against a lethal challenge with influenza A virus and significantly reduced weight
loss and lung virus titres. In addition, passive transfer of serum raised in rabbits against M2e–KLH
protected mice against a lethal influenza virus challenge, whereas serum from rabbits immunized
with SP1–KLH did not. Nevertheless, immunofluorescence staining revealed that rabbit serum
raised against SP1–KLH bound specifically to infected Madin–Darby canine kidney cells. We
conclude that the peptide SP1 contains an immunogenic epitope that is not sufficient for
immunoprotection.
Influenza is possibly the most important respiratory
infectious disease in humans worldwide. Yearly epidemics,
and more importantly occasional pandemics, often cause
considerable morbidity and mortality. Vaccination is the
most important protective measure against seasonal
influenza epidemics (Fiore et al., 2009). However, effective
vaccination against influenza is severely hampered by the
structural variability of haemagglutinin (HA) and neur-
aminidase, the two major antigens of the virus. This
frequent change in antigenic appearance is referred to as
‘drift’, while ‘shift’ refers to the emergence of a new HA
gene in the human influenza gene pool and is usually the
starting point of a new pandemic. Avian species are the
major reservoir of different HA genes. Occasionally, avian
influenza A subtypes cross the species barrier and might
initiate a pandemic, such as the highly pathogenic Spanish
flu during 1918–1919 and the recent, fairly mild, H1N1
swine influenza virus (H1N1v) pandemic (Dawood et al.,
2009). Different approaches have been followed to obtain
intra- or even heterosubtypic protective immunity, that is,
immunity to all influenza A strains regardless of subtype,
mainly by exploiting more-conserved influenza targets for
the development of novel vaccine candidates (Grebe et al.,
2008; Mozdzanowska et al., 2003; Neirynck et al., 1999).
We previously described an influenza vaccine based on the
highly conserved external domain of influenza matrix
protein 2 (M2e) linked to an appropriate carrier, such as
hepatitis B virus core particle (Neirynck et al., 1999). The
protection provided by M2e-based vaccination presumably
targets infected cells by a mechanism that is antibody- and
Fc receptor-dependent (Jegerlehner et al., 2004; Wang
et al., 2008).
Lamb et al. (1985) were the first to describe the influenza A
M2 protein as an ‘infected-cell surface antigen’ with a
minimum of 18 aa exposed on the cell surface. M2 is an
essential integral membrane protein of influenza virus that
forms a highly selective and pH-regulated proton channel
(Pinto et al., 1992). Although M2 protein is scarce on virus
particles, it is expressed abundantly on the surface of
infected cells (Lamb et al., 1985). These authors also
described an immune serum raised in rabbits by injecting a
9 aa peptide (SP1) that was chemically fused to the carrier
keyhole limpet haemocyanin (KLH). SP1 corresponds to
the N terminus of the mature influenza M2 protein. The
antiserum specifically bound to influenza-infected cells.
In this study, we compared the immunogenic and immun-
oprotective properties of the oligopeptide, SLLTEVETP
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(SP1), which consists of amino acids 2 to 10 of M2,
with the properties of the full-length M2e peptide
(SLLTEVETPIRNEWGCRCNDSSD). Each peptide was
coupled to KLH by using two different chemical conjuga-
tion reagents: glutaraldehyde or 1-ethyl-3-(3-dimethylami-
nopropyl)carbodiimide (EDC), as described by Lamb et al.
(1985). Sequence analysis of human isolates had revealed
the strongest conservation in the region of amino acids 2 to
10 of M2e. Therefore, in this study we investigated whether
antibodies to this small region are not only immunogenic
but also immunoprotective.
The SP1–KLH and M2e–KLH conjugates were used to
immunize BALB/c mice. The SP1–KLH and M2e–KLH
conjugates were supplemented with complete Freund’s
adjuvant for the first immunization and incomplete
Freund’s adjuvant for the second immunization. Mice
were immunized three times at 3-week intervals and
monitored for seroconversion to SP1 and M2e by using a
peptide ELISA (De Filette et al., 2005). Both M2e–KLH
conjugates induced serum IgG1, -2a, -2b and -3 antibodies
that specifically bound to SP1 peptide and M2e peptide in
an ELISA assay (Fig. 1 and data not shown). Also, immu-
nization with SP1 peptide fused to KLH with glutaralde-
hyde-induced serum IgG1 and IgG2a antibodies against
peptides SP1 and M2e (Fig. 1a–d). M2e–KLH conjugates
induced high titres of anti-M2e IgG1 and IgG2a, while the
SP1–KLH glutaraldehyde conjugate induced considerably
lower serum titres of anti-M2e IgG. The glutaraldehyde
coupling method resulted in a conjugate that was far more
immunogenic compared with EDC coupling, and similar
results have been reported for other antigens (Mera et al.,
2008). It is possible that EDC, which reacts with both
carboxylate and amino groups, generates various poly-
merized and randomly oriented conjugates, whereas
glutaraldehyde, which is a bifunctional coupling reagent,
links two compounds through their amino groups. Serum
IgG responses against the carrier KLH were similar in all
groups, indicating that the same amount of vaccine antigen
had been administered to the animals (Fig. 1e and f).
We next assessed the ability of SP1– and M2e–KLH
conjugates to elicit protection against a potentially lethal
influenza A virus challenge. BALB/c mice were immunized
as described before and 3 weeks after the last immuniza-
tion they were challenged with 4 LD50 of a mouse-adapted
PR8 strain. As expected, the challenge resulted in 80–100%
Fig. 1. Immunization of mice with SP1– or M2e–KLH conjugates
induces SP1- and M2e-specific serum IgG antibodies.
Glutaraldehyde (glu) and EDC, were used to link the SP1 and
M2e peptides to KLH. Hyperimmune serum was generated by
three immunizations at 3-week intervals. Results are expressed as
antigen-specific end point IgG1 (a, c and e) and IgG2a (b, d and f)
titres in pooled serum samples, as determined by M2e peptide
ELISA (a and b), SP1 peptide ELISA (c and d) and KLH ELISA (e
and f). White bars, First immunization; grey bars, first boost; black
bars, second boost.
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mortality in the control group, which was immunized with
KLH carrier and adjuvant (Fig. 2a). In contrast, vaccina-
tion with M2e–KLH conjugate resulted in complete
protection. The mortality rate of the SP1–KLH-vaccinated
mice was not significantly different from that of the KLH
control group, and the survival rates of these groups were
significantly lower than that of M2e–KLH-vaccinated mice,
all of which survived (P,0.001, Kaplan–Meier). Following
infection, all M2e–KLH vaccinated mice showed less
morbidity than the SP1–KLH and KLH groups (Fig. 2b).
The difference in body weight loss on day 6 after challenge,
between the SP1–KLH and KLH groups on one hand and
the M2e–KLH groups on the other, was highly significant
(P,0.005, Tukey test). We also determined viral titres by the
method of Reed and Muench (1938) in lung homogenates
prepared 6 days after infection with 1 LD50 of mouse-
adapted PR8. Mice immunized with either of the M2e–KLH
conjugates had significantly lower lung viral loads (P,0.05,
Tukey test) than the SP1–KLH vaccinated mice (Fig. 2c).
Since the immunogenicity of peptide antigens can differ in
different animal species (Darnule et al., 1980; Hanly et al.,
1995), we assessed the immunogenicity of SP1– and M2e–
KLH conjugates in rabbits. For the primer and first boost
injections, the peptide conjugates were supplemented with
Freund’s adjuvant. The second boost was composed of a
combination of free peptide and the corresponding
peptide–KLH conjugate. The last two boost immunizations
were with adjuvanted peptide alone as described by Lamb
et al. (1985). ELISA-based analysis of the serum IgG
responses against SP1 and M2e peptides revealed responses
of different strengths among the individual animals. The
strongest peptide-specific IgG responses were obtained
after the second immunization. Additional boosts with
peptide resulted in a slight decrease in serum IgG titres in
three of four animals (Fig. 3a and b). The antibody titres
against SP1 peptide were greater in SP1–KLH immunized
rabbits compared with M2e–KLH immunized rabbits.
These results, when compared with the data from the
active immunization of mice described above, indicate that
the SP1–KLH glutaraldehyde peptide conjugate is more
immunogenic in outbred New Zealand white rabbits than
in inbred BALB/c mice.
To test whether the anti-M2e and anti-SP1 antibodies
elicited in rabbits were protective, we injected naive BALB/c
mice intraperitoneally with these sera. Twenty four hours
after this passive transfer, the mice were challenged
intranasally with 4 LD50 of mouse-adapted PR8 virus
(Fig. 3c and d). All mice that received immune serum from
M2e–KLH-immunized rabbits survived the challenge,
while all those receiving anti-SP1–KLH immune serum
died (Fig. 3c). The difference in survival rate between the
M2e–KLH immune-serum recipients and the other two
groups was highly significant (P,0.001, Kaplan–Meier). In
addition, mice receiving anti-M2e–KLH rabbit serum
displayed limited morbidity (Fig. 3d, as compared with
the control group on day 6, P,0.001, Student’s t-test). The
protection was also reflected in the lung virus load (data
not shown). Based on these passive experiments and the
active immunization experiments described above, we
conclude that M2e peptide, when chemically linked to
KLH, can induce protective M2e-specific humoral
responses. In contrast, SP1–KLH fusions fail to elicit a
Fig. 2. Full-length M2e peptide coupled to KLH induces protective
immunity against PR8 influenza virus challenge, but SP1 peptide
coupled to KLH does not. Mice were immunized with SP1–glu (h),
SP1–EDC (D), M2e–glu (&) or M2e–EDC (m) peptide–KLH
conjugates, or with KLH (e) as control, and challenged with
4 LD50 of mouse-adapted PR8 virus. Survival (a) and body weight
(b) were monitored for 2 weeks after challenge. (c) Virus titre
(expressed as mean log10 TCID50 ml
”1) in lung extracts prepared
6 days after challenge. Differences in lung viral load between mice
vaccinated with M2e–KLH or SP1–KLH were statistically signifi-
cant (*, P,0.05, Tukey test).
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Fig. 3. Comparison of the antigenicity of SP1 and M2e and the protectiveness of SP1 and M2e immune sera. SP1 peptide
coupled to KLH induces fairly strong SP1-specific antibody responses but poor M2e-specific responses in rabbits. Rabbit
serum-IgG titres against M2e (a) and SP1 peptide (b) in hyperimmune antisera obtained after the first (black bars), second (dark
grey bars), third (white bars) and fourth (light grey bars) boosts. Rabbits 1 and 6 (R1 and R6) were immunized with M2e–KLH,
while rabbits 2 and 5 (R2 and R5) received SP1–KLH. The third and fourth boosts were with peptide only in the presence of
adjuvant. (c, d) Protection against a lethal influenza A virus challenge in mice after passive transfer of hyperimmune M2e–KLH
(&) or SP1–KLH (h) rabbit serum. After challenge with mouse-adapted PR8 virus, survival (c) and body weight (d) were
recorded for 2 weeks. (e) Indirect immunofluorescence staining of M2 on PR8 virus-infected MDCK cells. The upper and lower
panels show the surface fluorescent pattern after staining with rabbit anti-SP1–KLH (left) and rabbit anti-M2e–KLH IgG (right),
both revealed with donkey anti-rabbit IgG labelled with Alexa Fluor 488. The middle panel shows immunostaining of infected
cells with a goat anti-RNP serum obtained from the NIH Biodefence and Emerging Infections Research Resources Repository
from the National Institute of Allergy and Infectious Disease, National Institutes of Health, USA [polyclonal anti-influenza virus
RNP, A/Scotland/840/74 (H3N2), NR-3133]; Alexa Fluor 556-labelled donkey anti-goat was used as secondary antibody.
The lower panels show uninfected cells stained with SP1– and M2e–KLH immune sera. Exposure times for the SP1– and
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detectable protective immune response, even though they
are immunogenic in mice and rabbits.
It is possible that SP1–KLH immune serum does not
protect against influenza A virus challenge because the
anti-SP1 IgG fraction does not bind to natural M2, as
expressed on infected cells. To test this possibility, Madin–
Darby canine kidney (MDCK) cells were infected at an
m.o.i. of 1 with PR8 virus; mock-infected cells served as
negative controls. Twenty-four hours later we confirmed
infection by immunostaining with an antiserum specific
for influenza A virus nucleoprotein. Expression of M2 on
the surface of infected cells was confirmed by immuno-
staining with the M2e-specific mouse mAb 14C2 (not
shown). In parallel, cells were immunostained with serum
from SP1– or M2e–KLH-vaccinated rabbits. The SP1- and
M2e-immune-serum concentrations that were used were
normalized to obtain equal M2e-peptide-specific IgG titres,
as determined by M2e-peptide ELISA. The binding of M2e-
specific antibodies to the infected cells was revealed by
using rabbit IgG-specific Alexa 488-labelled antibodies.
M2e-specific antibodies in the rabbit M2e–KLH immune
serum readily bound to M2e expressed on the surface of
PR8-infected cells (Fig. 3e). In contrast, ,1% of PR8-
infected cells could be immunostained with the rabbit SP1–
KLH immune serum, a result that is in agreement with
published data (Lamb et al., 1985).
The first 8 aa residues of SP1 and M2e are identical to the
N terminus of M1 protein. The M1 protein is located
inside virus particles (Schulze, 1970) and virus-infected
cells (Bucher et al., 1989), and humoral immunity against
this protein does not protect mice against viral challenge
(Webster & Hinshaw, 1977). Therefore, it is possible that
the failure of SP1–KLH serum to protect could be due to a
relatively stronger reactivity of this serum with viral M1
protein compared with M2. Therefore, we examined
whether anti-SP1 antibodies react preferentially with M1
protein rather than with M2 protein (Fig. 3f). We
separated PR8 virion proteins by SDS-PAGE and com-
pared the reactivity of SP1– and M2e–KLH immune sera
with M1 and M2 proteins by Western blot analysis.
Binding of SP1–KLH serum to M2 could only be detected
after overexposure of the film (data not shown) and no
reactivity was observed with M1 protein (Fig. 3f). Rabbit
and mouse anti-M2e–KLH serum reacted strongly with
M2 protein and the M2e–KLH rabbit serum also reacted
with M1 protein (Fig. 3f). This result indicates that the
antiserum elicited by M2e–KLH immunization also
contains antibodies that specifically react with the SP1
region.
In summary, immune sera induced by SP1–KLH can
specifically bind to M2e exposed on the surface of influenza
virus-infected cells. However, all evidence obtained so far
indicates that this specific response fails to confer protection
against a lethal influenza A virus infection, but the reason
for this is not clear. The titre of SP1-specific antibodies
might not have been sufficiently high. Also, the avidity of
the average SP1–antibody–M2 interaction may have been
too weak to provide protection through antigen-dependent
cellular cytotoxicity. It is also possible that SP1 rarely adopts
a conformation similar to that of the native M2e on
influenza virus-infected cells or at least a conformation that
leads to the generation of immunoprotective antibodies.
Another possibility is that a fraction of the SP1-specific
antibodies bind to M2e sites but do not protect, while
another fraction is protective but is competed out by the
former, more abundant, fraction. However, we found no
evidence for the supposition that SP1–KLH and M2e–KLH
conjugates lead to different populations of IgG-subtypes.
Some of these hypotheses can be tested if sufficient
quantities of SP1–KLH immune antiserum are available.
To do this in mice would require an unrealistically large
number of animals, but another experimental animal
system might make such studies possible. We conclude
that, although the peptide comprising amino acids 2 to 10
of the M2 protein is highly conserved, it is not suitable for
the development of a universal influenza A vaccine because
it does not elicit protective antibodies.
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